← Back to all trials
Completed
NCT04821258
Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery for Colorectal Cancer
Conditions: Colorectal Cancer, Surgery--Complications
Sex: All
Ages: 18 Years – 85 Years
Healthy volunteers: No
Phase: NA
Enrollment: 48
Sponsor: Fundacin Biomedica Galicia Sur
Location: Complexo Hospitalario Universitario de Ourense Ourense
Summary
Most of Colorectal cancer (CRC) diagnosed are candidates for surgical resection with curative intent, although colorectal surgery is associated with some complications that could be life-threatening. Antibiotic prophylaxis is commonly used prior to the admission for the prevention of postoperative complications. However, this intervention can change the composition of intestinal microbiota and promote adverse inflammatory outcomes in CRC patients after surgery.
It seems the combination of different fungal extracts could be beneficial because of their role in gut microbiota modulation and their anti-inflammatory activity. Therefore, the fungal extract nutraceutical MICODIGEST 2.0 could be used to reduced the complications after CRC surgery.
Based on this hypothesis, we have designed a double-bind randomized clinical trial to evaluate the effect of MICODIGEST 2.0 on the complications after surgery with curative intent for CRC.
Eligibility Criteria
Inclusion Criteria:
1. CRC patients who are candidates for surgical treatment with curative intent (risk I-III).
2. American Society of Anesthesiologists' Physical Status Classification (ASA) \
Source: ClinicalTrials.gov (NCT04821258). StuddyBuddy aggregates publicly available trial information.
